Swooning markets a concern for stem cell companies

Recent setbacks in the stock market are particularly troubling for public stem cell companies, say analysts. With government funding to the field tightly restricted, the public markets have been a key source of funds for these developers. But investors tend to take a particularly skeptical view of early-stage development programs that are hard to understand. Merchant banker Steve Burrill told MarketWatch, though, that there are a number of potential sources of cash for stem cell companies around the world.

- read the report from MarketWatch

Related Articles:
NJ lawmakers back $270M stem cell program. Report
Stem cell research advances. Report